SMAD3 and Hepatic fibrosis: Conversely, treatment with dasatinib resulted in a significant 3.1-fold elevation in the hepatic level of smad-7 and a significant decline in smad-3 and collagen a1 by 49.2% and 51.9%, respectively compared to the liver fibrosis group (Figure 3(B–D)).